“alzheimers-disease” Archives

in
Entry Author Date Location
Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come 02/10/20 New York
Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s 02/10/20 National
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer 02/06/20 San Francisco
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More 01/31/20 National
Annovis Bio Gets $12M in IPO to Target Trio of Neurotoxic Proteins 01/29/20 New York
Biogen Strikes Alzheimer’s Deal, Paying $45M for Ionis Tau Drug Rights 12/19/19 San Diego
Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned 12/16/19 New York
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
3 Takeaways From the Resurrection of Biogen’s Alzheimer’s Drug 12/06/19 San Diego
Acadia Looks to Expand Drug Beyond Parkinson’s Disease Psychosis 12/06/19 San Diego
Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More 12/06/19 National
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results 12/05/19 National
As Alzheimer’s Conference Kicks Off, All Eyes Are on Biogen’s Drug 12/05/19 San Diego
6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost 12/04/19 New York
Alkermes Eyes Brain Disorders and Beyond With $100M Deal for Rodin 11/18/19 Boston
Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange 11/11/19 San Francisco
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More 11/08/19 National
Arkuda Unveils $44M and a Protein Restoration Approach to Dementia 11/07/19 Boston
Pinteon Gets $17M to Tackle Tau in Alzheimer’s, Other Brain Diseases 10/31/19 Boston
With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer 10/28/19 New York
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Biogen Reverses Course on Alzheimer’s Drug Analysis, Plans FDA Filing 10/22/19 Boston
Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO 10/01/19 New York
BACEless: Eisai, Biogen Pull Plug on Alzheimer’s Drug in Final Stage 09/13/19 Boston
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More 08/02/19 National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs 07/11/19 National
Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More 06/07/19 National
Bayer and Arvinas Join Forces in $115M Pharma & Ag Research Alliance 06/04/19 Boston
Two Days, Five Biotech IPOs, and $359M Raised for Clinical Trials 05/09/19 National
Page 2 of 7 « previous page · next page »